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OBJECTIVES The purpose of this study was to examine whether CD144-EMP (endothelium-derived
microparticles) is useful as a specific marker of endothelial cell (EC) dysfunction and to
determine whether plasma levels of circulating CD144-EMP predicted coronary artery
disease (CAD) in patients with type 2 diabetes mellitus (DM).
BACKGROUND Endothelial cell dysfunction is involved in atherogenesis; however, the quantitative assess-
ment of EC dysfunction has yet to be established clinically. Endothelium-derived micropar-
ticles are small, membrane-shed vesicles that are generated from the EC surface in response
to cellular dysfunction and/or injury. Diabetes mellitus is known to be associated with EC
dysfunction and accelerated atherosclerosis.
METHODS We characterized EMP using anti-CD144 (VE-Cadherin) antibody in various
atherosclerosis-related cells and investigated the association between the levels of CD144-
positive microparticles and hydrogen-peroxide–induced EC injury and acetylcholine-induced
coronary vasomotion. Furthermore, we evaluated plasma CD144-EMP levels in patients with
and without DM.
RESULTS We demonstrated that CD144-positive microparticles were derived selectively from human
EC. The levels of CD144-EMP reflected the degree of in vitro hydrogen-peroxide–induced
EC injury and impairment of in vivo endothelium-dependent coronary vasodilation (p 
0.01). Plasma CD144-EMP levels were increased significantly in DM patients compared
with patients without DM (p  0.001). In DM patients, the elevated levels of CD144-EMP
were the most significant risk factor for CAD relative to all other traditional risk factors (odds
ratio [OR] 3.5, 95% confidence interval [CI] 1.8 to 6.9, p  0.001). Notably, plasma
CD144-EMP identified a subpopulation of established CAD patients in DM subjects
without typical anginal symptoms (OR 10.6, 95% CI 3.9 to 29.5, p  0.001).
CONCLUSIONS The CD144-positive EMP exist in human plasma, and plasma CD144-EMP levels can be
a clinically specific and quantitative marker of EC dysfunction and/or injury. Measurement of
CD144-EMP, by providing a quantitative assessment of EC dysfunction, may be useful for
identifying DM patients with increased risk of CAD. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.0471622–30) © 2005 by the American College of Cardiology Foundation
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sndothelial cells (EC) play an important role in the
aintenance of vascular integrity and homeostasis, with EC
ysfunction having been implicated in the pathogenesis of
oth atherosclerosis and plaque instability (1–4). Recent
tudies have demonstrated that endothelial dysfunction is
lso a predictor of future coronary events and coronary
rtery disease (CAD) (3,5,6). Endothelial cell dysfunction
ay be detected clinically by measuring impairment of
ndothelium-dependent vasodilation (7,8) or by determin-
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005, accepted February 1, 2005.ng the plasma levels of circulating soluble markers (9,10).
hese methods, however, are either relatively nonspecific,
omplicated, or operator-dependent (11). A therapeutic
trategy based on the concept of vascular protection would
e valuable for preventing cardiovascular events and, accord-
ngly, there is a need to establish a practical and quantitative
arker of EC dysfunction and/or injury. In this regard,
everal recent studies have shown that the EC-plasma
embrane sheds small vesicles, termed endothelium-
erived microparticles (EMP), in response to either cellular
njury/dysfunction or apoptosis. This raises the possibility
hat the levels of EMP in the plasma may be a clinical
urrogate marker of in vivo EC dysfunction and/or injury
nd CAD (12–17).
Currently the number of patients with type 2 diabetes
ellitus (DM) is increasing in the population. Diabetes
ellitus is an established risk factor for accelerated athero-
clerosis, with EC dysfunction thought to be a key factor
nvolved in the pathogenesis of athero-thrombogenic dia-
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May 17, 2005:1622–30 Endothelial Microparticles and CAD in Diabetesetic complications. Acute coronary syndromes resulting
rom plaque rupture and erosion are commonly found in
atients with DM (18–20), and even after intensive medical
anagement, myocardial infarction and stroke frequently
ccur in these patients (20,21). Furthermore, silent myocar-
ial ischemia is a common feature in DM patients, and it is
clinically important to detect CAD among DM patients
ith no symptoms or signs suggestive of CAD (22). In the
resent study, we investigated whether CD144-EMPs were
seful as a specific marker of EC dysfunction and deter-
ined whether plasma levels of circulating CD144-EMPs
redicted CAD in patients with type-2 DM.
ETHODS
ell culture and blood cell preparations. Human coro-
ary artery endothelial cells (HCAEC) (Lot:3F0175, Cam-
rex Bio Science Walkersville Inc., Walkersville, Maryland)
ere cultured in medium-199 containing 10% fetal calf
erum (FCS), heparin, and endothelial cell growth supple-
ent (BD Bioscience, San Jose, California), while human
ortic smooth muscle cells (HAoSMC) (Cambrex Bio
cience Walkersville Inc.) were cultured in Dulbecco’s
odified Eagle medium-containing 20% FCS and human
onocyte-derived macrophages in RPMI-1640 containing
0% heat-inactivated human serum. Peripheral blood
ononuclear cells were prepared by density gradient cen-
rifugation (d  1.077 g/ml) and then plated onto a culture
ish in order to separate adherent monocytes. Platelet-rich
lasma was separated from citrated peripheral blood by
entrifugation at 160 g for 10 min. The platelet-rich plasma
as then centrifuged at 15,000 g for 30 min and the
latelet-pellet was re-suspended in phosphate-buffered sa-
ine (PBS).
luorescence microscopy and flow cytometric analysis of
D-144 in EC. Human coronary artery endothelial cells
Abbreviations and Acronyms
ACh  acetylcholine
CAD  coronary artery disease
CI  confidence interval
DM  diabetes mellitus
EC  endothelial cells
EMP  endothelium-derived microparticles
FCS  fetal calf serum
FITC  fluorescein isothiocyanate
HAoSMC human aortic smooth muscle cells
HCAEC  human coronary artery endothelial cells
HDL  high-density lipoprotein
hs-CRP  high-sensitivity C-reactive protein
LAD  left anterior descending coronary artery
LDL  low-density lipoprotein
LMT  left main trunk coronary artery
OR  odds ratio
PBS  phosphate-buffered saline
sICAM-1  soluble intercellular adhesion molecule-1ere plated onto a fibronectin-coated glass dish and incu- fated with bis-benzimide and a fluorescein isothiocyanate
FITC)-conjugated antibody against CD144 (VE-
adherin) (Serotec Ltd., Oxford, United Kingdom). After
ashing the culture with PBS, we measured expression of
D144 in the cells using fluorescence microscopy. For the
ow cytometric analyses, the cultured HCAEC were de-
ached with cold PBS containing ethylenediaminetetraace-
ic acid and re-suspended in PBS containing 1% FCS and
.1% sodium azide. The cells were then incubated for 30
in with CD144-FITC or control-IgG-FITC, followed by
ashing and analysis of CD144 expression by FACScalibur
Becton Dickinson, Franklin Lakes, New Jersey).
haracteristics of atherosclerosis-related cell-derived
icroparticles. In order to generate atherosclerosis-related
ell-derived microparticles, each cell preparation was stim-
lated with a lethal concentration of hydrogen peroxide
H2O2) (15) followed by a further 2 h incubation. The
ulture medium containing microparticles was then col-
ected and centrifuged at 5,000 g for 10 min to remove crude
ell debris and nuclei, with the supernatant then being
ltracentrifuged for a further 2 h at 100,000 g (16,23). The
ellets of microparticles were then re-suspended in PBS
efore labeling with either CD144-FITC, CD31-FITC
BD Pharmingen, San Diego, California), or control-IgG-
ITC. Furthermore, the isolated human platelet-derived
icroparticles were incubated with CD31-FITC and
D42b-phycoerythrin (BD Pharmingen) for 30 min. The
reparations were analyzed by FACScalibur with CellQuest
oftware (Becton Dickinson), with microparticles being
efined as elements with a size1.5 m relative to standard
eads (4.2 m).
ssay of endothelial cell death induced by H2O2. Human
oronary artery endothelial cells were cultured on six-well
lates until confluent followed by exposure for 2 h to various
oncentrations of H2O2. The culture medium was collected
or analysis of EMP levels using FACScalibur. The remain-
ng adherent HCAECs were then washed with medium-
99, and cell viability was measured by the MTS Assay Kit
Promega, Madison, Wisconsin), with the percentage of
ead cells calculated as described previously (4).
linical study population. The study incorporated enroll-
ent of 232 consecutive Japanese patients with DM who
ad coronary artery angiography at Kumamoto University
ospital. Fifteen patients with acute phase and unstable
onditions including severe valvular disease (n  3), active
nfection (n  1), untreated malignant diseases (n  2),
ctive autoimmune disease (n  4), and severe congestive
eart failure (n  5) were excluded. Coronary artery disease
as defined as angiographic evidence of stenosis in more
han 75% of the major coronary arteries. The study also
ncluded 102 nondiabetic patients without angiographic
vidence of CAD (10% stenosis in coronary arteries) or
arotid plaques determined by ultrasound (maximum
ntima-media thickness in the common carotid artery 1.1
m) as a control group. Informed consent was obtained
rom all patients before the study, which was carried out in
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Endothelial Microparticles and CAD in Diabetes May 17, 2005:1622–30ccordance with the guidelines approved by the ethics
ommittee at our institution.
easurement of circulating plasma levels of CD144-
MP and sICAM-1. Blood samples were drawn by veni-
uncture into blue-top vacutainer tubes containing sodium
itrate after a 12-h overnight fast, before any mechanical
ntervention. Blood samples were assayed immediately after
enipuncture. Platelet-rich plasma was separated from
hole blood by centrifugation at 160 g for 10 min. The PRP
as then centrifuged at 6,000 g for 1 min to prepare
latelet-poor plasma. For the EMP assay, 50 l platelet-
oor plasma in TruCount tubes (Becton Dickinson) was
ncubated with CD144-FITC and CD42b-phycoerythrin
or 30 min. Then 1 ml of PBS buffer was added and the
ample was ready for flow cytometry. Endothelium-derived
icroparticles were defined as elements with CD144-
ositivity and CD42b-negativity with a size 1.5 m
12,13). We calculated the absolute number of EMPs as
escribed previously (24). We also measured plasma levels
f soluble intercellular adhesion molecule-1 (sICAM-1),
elated to endothelial dysfunction and CAD (9,11), by
ICAM-1 ELISA (R & D Systems Inc., Minneapolis,
innesota).
uantitative coronary angiography and measurement of
oronary blood flow. Quantitative coronary angiography
nd measurement of coronary blood flow were performed in
rder to assess EC dysfunction as described previously
7,25,26). Quantitative coronary angiography was per-
ormed in 31 patients without CAD in the same manner, as
escribed (25). After baseline angiography, graded concen-
rations of acetylcholine (ACh: 10, 50 g/min) were infused
irectly into the left main trunk coronary artery (LMT)
hrough a Judkins catheter for 2 min. The trunk of the left
nterior descending coronary artery (LAD) was divided into
roximal, mid, and distal segments of equal length. The
umen diameter at the center of each segment was measured
uantitatively with the use of a computer-assisted coronary
ngiographic analysis system (Cardio 500, Kontron Instru-
ents, München, Germany) by two observers blinded to the
tudy protocol. Coronary artery diameter responses to ACh
10, 50 g/min at LMT) were expressed as percentage
hange from baseline coronary artery diameters.
Coronary blood flow velocity was measured in 24 of 31
atients by using 0.014-inch wire, equipped with a Doppler
rystal at its tip (Flow Wire, Cardiometrics, Mountain
iew, California), that was advanced through the Judkins
atheter and carefully positioned in the straight proximal
egment of the LAD as described previously (25). The
table peak flow velocity signals at baseline and during a
-min infusion of ACh (10 g/min at LMT) were used for
nalysis (Flow Map, Cardiometrics). Coronary blood flow
as calculated from blood velocity and arterial diameter.
he response of coronary blood flow to intracoronary
nfusion of ACh (10 g/min at LMT) was expressed as a
ercentage change from the value of the baseline blood flowust before ACh infusion. After an additional 10 min, Entracoronary infusion of isosorbide dinitrate (1 mg) was
iven. Hemodynamic measurements and coronary angiog-
aphy were repeated before and at each of the infusions.
tatistical analysis. The statistical analyses were per-
ormed with Stat View-V software (SAS Institute, New
ork, New York). Results were expressed as mean  SE.
igh-sensitivity C-reactive protein (hs-CRP), triglycerides,
asting plasma glucose, hemoglobin A1c, and CD144-EMP
evels were expressed as medians and interquartile range.
omparisons of plasma EMP levels in control, DM without
AD, and DM with CAD were determined by one-way
nalysis of variance. The frequencies for gender, smoking,
nd hypertension were compared between the two groups by
sing chi-square analysis. Comparisons between two groups
ere carried out using the unpaired t test (normal distrib-
ted variables: age, body mass index, total cholesterol, LDL
holesterol, HDL cholesterol, and sICAM-1) and the
onparametric Mann-Whitney U test (triglycerides, hs-
RP, fasting plasma glucose, hemoglobin A1c, and
D144-EMP). Univariate and multivariate logistic regres-
ion analyses were performed to determine the relationship
etween EMP and other factors, using the following factors
s categorical covariates defined according to the cutoff
oints of the American Heart Association (27): age
75years, hypertension systolic blood pressure 140 mm
g, diastolic blood pressure 90 mm Hg or taking an
ntihypertensive drug, high body mass index 25 kg/m2,
igh total cholesterol 240 mg/dl, high LDL 160 mg/dl,
ypertriglyceridemia 150 mg/dl, low HDL 40 mg/dl,
igh fasting plasma glucose 126 mg/dl, high hemoglobin
1c (HbA1c) 7.0%, or increased hs-CRP 3.0mg/l. The
MP data were logarithmically transformed (log EMP) to
btain a normal distribution and were then analyzed using
inear regression analysis. A p value 0.05 was considered
tatistically significant.
ESULTS
D144-positive microparticles are identified as specific
icroparticles derived from EC. Figure 1A shows intense
D144 (VE-cadherin) immunostaining in HCAEC local-
zed at the cell-cell marginal contacts. No CD144 staining
as observed in HAoSMC, monocyte-derived macro-
hages, lymphocytes, or platelets (data not shown). The
ACS analysis demonstrated that HCAEC expressed
D144 with a mean fluorescence intensity of 37.2  4.6
Fig. 1B). Figure 1C shows that HCAEC-derived micro-
articles expressed CD144, whereas microparticles derived
rom HAoSMC, monocyte-derived macrophages, lympho-
ytes, or platelets did not express this marker (Figs. 1D to
H). Microparticles from endothelial cells and platelets
ere positive for CD31 (Figs. 1I and 1J) and CD31
ositive-CD42b negative microparticles were generated
rom isolated human platelets (Fig. 1K). These results
emonstrated that only CD144 was a specific marker of
MP.
F
s
C
(
F
l
H
s
1625JACC Vol. 45, No. 10, 2005 Koga et al.
May 17, 2005:1622–30 Endothelial Microparticles and CAD in Diabetesigure 1. (A) An immunofluorescent photomicrograph showing CD144-expression in human coronary artery endothelial cells (HCAEC). The green
ignal indicates fluorescein isothiocyanate (FITC)-CD144 while the blue signal indicates the nucleus (n  4). (B) A histogram analysis of
D144-expression in HCAEC detected by FACScalibur. The thin line represents control immunoglobulin G (IgG) and the thick line represents CD144
n  5). (C to H) Histogram analyses of CD144-expression in microparticles derived from a variety of cells involved in atherosclerosis detected using
ACScalibur. (C) HCAEC; (D) HAoSMC (human aorta smooth muscle cell); (E) platelets; (F) lymphocytes; (G) monocytes; (H) macrophages. The thin
ines represent control IgG and the thick lines represent CD144 (n  5). (I to J) Histogram analyses of CD31-expression in microparticles derived from
CAEC and platelets. (K) Representative dot-plot graphs of microparticles expressing CD31-CD42b derived from human platelets. The lower right
ection of graph shows CD31-positive and CD42b-negative microparticles derived from isolated human platelets.
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Endothelial Microparticles and CAD in Diabetes May 17, 2005:1622–30D144-EMP levels in culture medium are associated
ith H2O2-induced EC death in vitro. Exogenous H2O2
ver the concentration range 50 to 800 mol/l caused injury
n HCAEC in a concentration-dependent manner as as-
essed by MTS assay (Fig. 2A). This concentration range of
2O2 also simultaneously increased EMP levels in the
ulture medium in a concentration-dependent manner (Fig.
A). The linear regression analysis demonstrated a signifi-
ant positive correlation between EC injury evaluated by the
TS assay and EMP levels in cultured HCAEC (r 0.79,
 0.002; Fig. 2B).
lasma CD144-EMP are associated with endothelial
ysfunction in human coronary arteries in vivo. Micro-
articles in human plasma were defined as elements with a
ize 1.5 m relative to standard beads (Fig. 3A). A
istogram analysis of the distribution of EMPs expressing
D144 in human plasma is shown in Figure 3B. Figures 3C
nd 3D are representative dot-plot graphs of EMP express-
ng CD144-CD42b in patients with or without DM. The
ower right sections of the graphs indicate EMP in plasma
s CD144-positive and CD42b-negative microparticles.
e demonstrated that CD144-EMP had a significant
orrelation with coronary vasomotion of the proximal seg-
ent (r0.547, p 0.001; Fig. 4A) in response to ACh
endothelium-dependent vasodilation) (10 g/min),
hereas sICAM-1 (commonly used soluble plasma marker
f EC dysfunction) was not correlated (r  0.309, p 
.09; Fig. 4B). Figure 4C also demonstrates that there is a
trong significant inverse correlation between CD144-EMP
evels and percentage change of coronary diameter by ACh
50 g/min) at the proximal segment (r  0.763, p 
.001), whereas sICAM-1 was weakly correlated (r 
0.407, p  0.02; Fig. 4D). Furthermore, only CD144-
MP was independently and significantly associated with
ercentage change of coronary diameter at the proximal
egment in response to ACh (50 g/min) by multiple
egression analysis (r  0.704, p  0.001). The plasma
D144-EMP levels also had a significant correlation with
oronary vasomotion in response to graded concentrations
igure 2. (A) A bar graph showing CD144-EMP (endothelium-derived
icroparticles) levels in cultured medium of HCAEC and the number of
ead HCAEC after exposure for 2 h to various concentrations of H2O2.
he solid bars represent CD144-EMP levels and open bars represent the
umber of dead HCAEC (n  4) (B) A linear-regression graph demon-
trating the significant correlation between the number of dead HCAECs1
nd CD144-EMP levels in cultured medium after exposure to various
oncentrations of H2O2 (r 0.791, p 0.002). Abbreviations as in Figure 1.f ACh (10, 50 g/min) at the mid and distal segments of
he LAD (mid: 10 g/min, r  0.472, 50 g/min, r 
0.661; distal: 10 g/min, r  0.536, 50g/min, r 
0.507; p  0.01) as well as proximal segment.
Figures 4E and 4F also demonstrate that plasma levels of
D144-EMP and sICAM-1 have a significant inverse
orrelation with coronary blood flow in response to ACh
10 g/min) (CD144-EMP: r  0.588, p  0.01;
ICAM-1: r0.457, p 0.02). Only CD144-EMP was
ndependently and significantly correlated with ACh-
nduced coronary blood flow by multiple regression analysis
r0.491, p 0.01). In contrast, levels of CD144-EMP
id not have a significant association with endothelium-
ndependent vasodilation by isosorbide dinitrate at the
roximal, mid, and distal segments of the LAD (proximal:
 0.07, p  0.7; mid: r  0.09, p  0.6; distal: r  0.07,
 0.7).
levated plasma levels of CD144-EMP and sICAM-1 in
atients with DM. The baseline clinical characteristics of
he patients in the study are summarized in Table 1. The
evels of circulating CD144-EMP in patients with DM
ere significantly greater than in nondiabetic control pa-
ients (0.602 [0.476 to 0.783]  106/ml vs. 0.310 [0.204 to
.405]  106/ml, p  0.001; Fig. 5A). Furthermore,
D144-EMP levels in DM patients with CAD were
ignificantly higher than in those without CAD (0.706
0.577 to 1.067]  106/ml vs. 0.541 [0.423 to 0.652] 
igure 3. (A) Forward scatter (FSC) and side scatter (SSC) analysis of
icroparticles in human plasma. The section containing microparticles was
ated using a size1.5 m in FSC-SSC scatter using standard beads (bead
ize 4.2m). (B) A histogram analysis of CD144-expression in the gated
icroparticles in human plasma. The thin line represents control-IgG and
he thick line represents CD144. (n 5) (C to D) Representative dot-plot
raphs of microparticles expressing CD144-CD42b in human plasma in
atients with or without DM. The lower right section of each graph
ontains EMP as CD144-positive and CD42b-negative microparticles.
M  diabetes mellitus; other abbreviations as in Figures 1 and 2.06/ml, p  0.001; Fig. 5B). We also found that circulating
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May 17, 2005:1622–30 Endothelial Microparticles and CAD in DiabetesD144-EMP levels in DM patients without CAD were
ignificantly elevated compared with the control group
0.541 [0.423 to 0.652] 106 counts/ml vs. 0.310 [0.204 to
.405]  106 counts/ml, p  0.001; Fig. 5B). The levels of
irculating sICAM-1 in DM patients were elevated signif-
cantly compared with the control group (186.6 3.9 ng/ml
s. 163.6  5.2 ng/ml, p  0.003), and the plasma levels of
ICAM-1 in DM patients with CAD were higher than
M patients without CAD (193.3 5.9 ng/ml vs. 177.7
.1 ng/ml, p  0.04).
lasma levels of CD144-EMP, but not sICAM-1, pre-
icted presence of CAD in patients with DM. The
nivariate logistic-regression analyses showed that higher
evels of CD144-EMP (0.78 106/ml; 75th percentile of
he distribution of EMP in patients with DM), longer
uration of DM (12 years; 75th percentile of the distri-
ution of DM in the present study) (28), high LDL
holesterol, low HDL cholesterol, and hypertension were
igure 4. (A to D) Linear regression analysis showing the relationship
etween plasma levels of CD144-EMP or soluble intercellular adhesion
olecule-1 (sICAM-1) and percentage change in coronary artery luminal
iameter at the proximal segment of LAD in response to intracoronary
cetylcholine (10 g/min, 50 g/min at left main trunk coronary artery
LMT]) infusion. Open circles are nondiabetic control patients and filled
ircles are patients with DM. (E to F) Correlation between plasma levels
f CD144-EMP or sICAM-1 and percent increase from baseline values of
oronary blood flow in response to intracoronary infusion of acetylcholine
10 g/min at LMT). Open circles are nondiabetic control patients and
lled circles are patients with DM. Abbreviations as in Figures 1 to 3.ignificant risk factors for the presence of CAD in patients sith DM. However, high sICAM-1 levels (215.0 ng/ml;
5th percentile of the distribution of sICAM-1 in patients
ith DM) could not detect presence of CAD in patients
ith DM by the univariate analysis. There was no signifi-
ant relationship between CAD and other risk factors such
s increased levels of fasting glucose and HbA1c (Table 2).
he multivariate analysis indicated that an elevated
D144-EMP level was the most significant and indepen-
ent risk factor for CAD in patients with DM (Table 3).
Notably, the plasma CD144-EMP levels identified a
ubpopulation of DM patients who had CAD without
ypical chest symptoms (odds ratio [OR] 10.6, 95% confi-
ence interval [CI] 3.9 to 29.5, p  0.001).
ISCUSSION
his study demonstrated that CD144-positive EMP exists
n human plasma and that plasma levels of these micropar-
icles are associated clinically with coronary endothelial
ysfunction and/or injury. We also found significantly
levated levels of CD144-EMP in patients with DM
ompared with nondiabetic control patients. CD144-EMP
evels were significantly higher in DM patients with CAD
han in those without CAD, with the elevated CD144-
MP levels being found to be a significant independent
redictor for the presence of CAD in patients with DM. Of
articular interest was our finding that higher CD144-EMP
evels were a significant risk factor for the presence of CAD
n patients without symptomatic episodes of angina.
Microparticles are small membrane-shed vesicles exhib-
ting various biological activities that are released from many
ifferent cell types into the extracellular space in response to
ither cellular injury/dysfunction or apoptosis (15,29). Pre-
ious reports have defined circulating EMP as particles
1.5 m in size that reacted positively with several non-
pecific EC markers such as CD31 (12,13,17). Recent
tudies investigating the possible contribution of EMP to
uman diseases defined these particles arbitrarily as CD31-
ositive and CD42b-negative microparticles and showed
hat the circulating CD31()-CD42b()-EMP was ele-
ated in patients with hypertension and acute coronary
yndromes, and the EMP levels correlated significantly with
lasma levels of platelet microparticles (12,17). CD31 is
xpressed abundantly in platelets, and we observed that
D31()-CD42b() microparticles were also generated
rom isolated human platelets in vitro (Fig. 1K). We also
ound CD31()-CD42b() EMP in plasma contained
D61P-positive microparticles with 30  5.3% on histo-
ram analysis (n  5, date not shown). Taken together,
hese results suggest that the plasma CD31()-CD42b()
MP detected in these earlier studies may include platelet
icroparticles and that the levels of these EMP cannot
ccurately reflect EC dysfunction and/or injury. In our
tudy, we used vascular endothelial cadherin (VE-cadherin;
D144) to identify EMP, as this molecule is expressedpecifically by only EC to maintain stability of the EC-
a
(
C
s
v
h
p
a
b
d
e
t
i
d
r
e
p
e
t
l
t
l
W
o
d
W
c
h
w
c
t
i
T
f
A
C
H
B
T
L
T
H
F
H
H
D
s
E
B
L  h
F
i
p
c
p
l
t
p
1628 Koga et al. JACC Vol. 45, No. 10, 2005
Endothelial Microparticles and CAD in Diabetes May 17, 2005:1622–30dherens junction and also suppresses apoptosis of EC
30,31). Using this approach, we demonstrate that
D144-EMPs are endothelial specific microparticles as-
ociated with in vitro EC injury in cultured human
ascular endothelial cells and CD144-EMP exists in
uman plasma.
Endothelial dysfunction is a systemic disorder that
lays a critical role in the pathogenesis of atherosclerosis
nd its complications (4,6). In the past, EC function has
een assessed by measuring either endothelium-
ependent vasodilation or plasma levels of soluble mark-
rs. Although these two methods are useful for evaluating
he condition of the vasculature, with abnormal results
nitiating treatment to prevent atherosclerosis and car-
iovascular complications (7–10), a quantitative, compa-
able, and specific marker of EC dysfunction has yet to be
stablished. Brachial artery imaging during reactive hy-
eremia using high-resolution ultrasound is also used
Table 1. Clinical Characteristics of the Subject
(
Men/women, n
Age, yrs 6
Body mass index, kg/m2 2
Hypertension, n (%)
Current smoking, n (%)
Total cholesterol, mg/dl 19
LDL cholesterol, mg/dl 11
HDL cholesterol, mg/dl 5
Triglycerides, mg/dl (IQR) 97.0
High-sensitivity CRP, mg/l (IQR) 0.50
Fasting plasma glucose, mg/dl (IQR) 95.5
Duration of diabetes, yrs
Hemoglobin A1c, % (IQR) 5.2
Medication therapy
Sulfonylurea, n (%)
Alpha-glucosidase inhibitor, n (%)
Insulin, n (%)
Values are mean  SE. High-sensitivity CRP, triglycerides,
as medians (interquartile range).
CRP  C-reactive protein; DM  diabetes mellitus; HD
low-density lipoprotein.
igure 5. (A) Box-and-whisker plot showing plasma CD144-EMP values
n patients with and without DM. (B) Box-and-whisker plot showing
lasma CD144-EMP values in control patients, DM patients with
oronary artery disease (CAD), and DM patients without CAD. In these
lots, lines within boxes represent median values; the upper and lower
ines of the boxes represent the 25th and 75th percentiles, respectively; andm
c
he upper and lower bars outside the boxes represent the 90th and 10th
ercentiles, respectively. Abbreviations as in Figures 1 to 3.xtensively as a noninvasive method to determine endo-
helial dysfunction, although this method suffers from a
ack of standardization as a result of considerable opera-
or dependence of several technical aspects (11). Plasma
evels of thrombomodulin, adhesion molecules, and Von
illebrand factor are used commonly as soluble markers
f endothelial dysfunction, although neither molecule is
erived specifically from dysfunctional endothelium (10).
e also observed that there was a significant inverse
orrelation between circulating levels of CD144-EMP in
uman plasma and endothelial-dependent vasodilation as
ell as coronary blood flow response to acetylcholine in
oronary artery. Taken together, these results indicate
hat CD144-EMP can be a specific marker for quantify-
ng endothelial dysfunction and/or injury.
able 2. Univariate Logistic Regression Analysis of Risk Factors
or CAD in Patients With DM
OR (95% CI) p Value
ge (75 yrs) 1.8 (0.9–3.4) 0.07
urrent smoking (yes) 1.1 (0.6–2.1) 0.7
ypertension (yes) 2.0 (1.1–3.4) 0.01
ody mass index (high) 0.9 (0.5–1.5) 0.7
otal cholesterol (high) 0.8 (0.4–1.7) 0.6
DL cholesterol (high) 2.9 (1.3–6.3) 0.008
riglycerides (high) 1.0 (0.6–1.8) 0.9
DL cholesterol (low) 2.2 (1.1–4.3) 0.02
asting plasma glucose (high) 0.8 (0.5–1.4) 0.4
emoglobin A1c (high) 1.1 (0.7–1.9) 0.6
igh-sensitivity CRP (high) 1.8 (0.9–3.6) 0.07
uration of DM (long 12 yrs) 1.9 (1.1–3.4) 0.02
ICAM-1 (high 215.0 ng/ml) 1.4 (0.7–2.5) 0.3
MP (high 0.78  106/ml) 4.1 (2.2–7.7) <0.001
old indicates significant values.
CAD  coronary artery disease; CI  confidence interval; EMP  endothelial
rol
02)
DM
(n  232) p Value
6 147/85 0.2
1.2 66.6  0.6 0.6
0.9 24.0  0.2 0.5
4) 144 (62) 0.01
6) 49 (21) 0.3
3.0 201.0  2.6 0.05
2.4 122.2  2.2 0.08
1.7 53.3  1.0 0.05
–129.0) 117.0 (89.0–161.5) 0.01
–1.00) 1.30 (0.50–3.50) 0.01
–107.0) 126.0 (106.0–159.8) 0.001
10.0  0.6 —
5.6) 6.7 (6.1–7.7) 0.001
93 (40) —
50 (22) —
48 (21) —
plasma glucose, and hemoglobin A1c levels were expressed
igh-density lipoprotein; IQR  interquartile range; LDL s
Cont
n  1
56/4
6.1 
4.4 
45 (4
16 (1
1.3 
5.5 
8.0 
(72.0
(0.30
(89.0
—
(4.9–
—
—
—
fastingicroparticle; OR  odds ratio; sICAM-1  soluble intercellular adhesion mole-
ule-1; other abbreviations as in Table 1.
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May 17, 2005:1622–30 Endothelial Microparticles and CAD in DiabetesIt is well established that endothelial dysfunction is a key
eature of type 2 DM and is thought to be a crucial cause of
iabetic cardiovascular complications. As myocardial isch-
mia and myocardial infarction occur frequently in patients
ith DM without typical chest symptoms (22), it is often
ifficult to determine clinically whether or not DM patients
ave CAD (32). In the present study, we found that plasma
evels of CD144-EMP were elevated significantly in pa-
ients with DM compared with nondiabetic control pa-
ients, and that higher levels of CD144-EMP predicted the
resence of CAD in patients with DM. Furthermore,
lasma CD144-EMP levels appeared to reveal the presence
f CAD in DM patients without typical chest pain. On the
asis of these findings, we propose that CD144-EMP may
e a useful surrogate marker for identifying patients with
M with an increased risk of atherosclerosis. Furthermore,
e also found that the plasma levels of CD144-EMP in 120
AD patients without DM (0.645 [0.534 to 0.817] 
06/ml) were elevated significantly compared with control
roups and DM patients without CAD (Koga et al.,
npublished observation, November 2004). As a next step,
e need to investigate the pathophysiologic roles of EMP in
he development of atherosclerosis and to examine in large
linical trials whether CD144-EMP is a prognostic marker
or future cardiovascular events.
In conclusion, we demonstrated the presence of CD144-
MP in human plasma, with increased levels being found in
atients with DM, especially in those individuals with
AD. Therefore, VE-cadherin positive EMPs may be a
seful surrogate marker for evaluating endothelial dysfunc-
ion and/or injury. Treatment of atherosclerotic patients
hat focuses on the integrity and condition of ECs based on
ssessments of plasma CD144-EMP levels may provide
otential therapeutic strategies for preventing cardiovascular
omplications.
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